2027 Southern Hemisphere Influenza Vaccine

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2DP26R0002

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

UNITED STATES

SourceSAM
Documents2
The Defense Logistics Agency (DLA) Troop Support, a component of the U.S. Department of Defense, has issued a solicitation for the supply of the Southern Hemisphere Influenza Vaccine for the 2027-2028 flu season. This procurement, identified under solicitation number SPE2DP26R0002, seeks to secure approximately 30,000 doses of influenza vaccine, with the final quantity subject to adjustment based on the definitive requirements of the supported military services. The contract will be structured as an indefinite quantity contract, with a guaranteed minimum of 75% and a maximum of 150% of the estimated annual quantity, providing flexibility to accommodate fluctuating demand. The primary objective of this procurement is to ensure the timely and reliable delivery of FDA-approved and CDC ACIP-recommended influenza vaccines for use in healthy individuals aged six months and older. Each vaccine dose must be pre-measured at 0.5 mL and supplied in a commercially available, pre-filled syringe suitable for intramuscular administration. The specific vaccine formulation for the 2027-2028 season will be determined by the FDA’s Vaccines and Related Biological Products Advisory Committee, and all products must meet the latest regulatory and clinical recommendations at the time of delivery. All vaccine doses are to be delivered to the Defense Depot in New Cumberland, Pennsylvania. The preferred delivery schedule requires that 100% of the contracted quantity be delivered by March 12, 2027, though alternative delivery schedules may be considered. Contractors must demonstrate the capability to meet this delivery timeline and comply with all associated logistical requirements. This opportunity is classified under NAICS code 325414 (Biological Product [except Diagnostic] Manufacturing), with a Product Service Code of 6505, and is open to qualified manufacturers with the requisite FDA approvals and ACIP recommendations for their vaccine products. National Stock Numbers for the awarded products will be established at the time of contract award. Interested parties are encouraged to review the full solicitation, which will be posted on both the DLA Bid Board System (DIBBS) and SAM.gov. The anticipated solicitation release date is September 28, 2026, with responses due by October 14, 2026; however, DLA reserves the right to adjust these dates as necessary. Prospective offerors are advised to monitor these platforms for updates and to set up automated notifications for any changes to the solicitation. For further information or to submit questions, interested contractors may contact the primary point of contact, Rosbert Jones ([email protected], 445-737-1254), or the secondary contact, Melissa Rios Thomas ([email protected], 445-737-8646). This procurement represents a significant opportunity for qualified vaccine manufacturers to support the health and readiness of U.S. military personnel by providing critical immunization products in accordance with stringent federal standards and delivery requirements.